Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

MRK Factor-Based Stock Analysis - Peter Lynch July 09, 2025 — 09:03 am EDT Written by John Reese for Validea -> Below is Validea's guru fundamental report for MERCK & CO INC (MRK).

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and pressures. Learn why MRK stock is a buy.

Cantor Fitzgerald’s analysis suggests the Verona acquisition would enhance Merck’s top-line growth profile, even without considering potential revenue synergies from the combined operations.

The downgrade comes as Merck plans to acquire Verona Pharma for $107 per share, representing approximately a 23% premium to the stock’s previous trading price.

According to Benzinga Pro, Merck & Co's peer group average for short interest as a percentage of float is 3.74%, which means ...

EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.

Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study outcomes.